Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double …
Background Bevacizumab and erlotinib target different tumour growth pathways with little
overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial …
overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial …
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non–small cell lung cancer
Abstract Background The NCIC Clinical Trials Group conducted the BR. 21 trial, a
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …
FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell …
8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …
[HTML][HTML] First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular …
AMC Dingemans, AJ de Langen, V Van Den Boogaart… - Annals of oncology, 2011 - Elsevier
Background Both bevacizumab and erlotinib have clinical activity in non-small-cell lung
cancer (NSCLC). Preclinical data suggest synergistic activity. Patients and methods …
cancer (NSCLC). Preclinical data suggest synergistic activity. Patients and methods …
Clinical experience with erlotinib in non-small-cell lung cancer.
E Felip, R Rosell - Drugs of Today (Barcelona, Spain: 1998), 2006 - europepmc.org
Lung cancer is the leading cause of cancer death worldwide. Despite the introduction of
more-effective chemotherapeutic agents, it appears that a survival plateau has been …
more-effective chemotherapeutic agents, it appears that a survival plateau has been …
Erlotinib in the treatment of non-small cell lung cancer
ER Brown, FA Shepherd - Expert review of anticancer therapy, 2005 - Taylor & Francis
Inhibition of the epidermal growth factor receptor is one of the most promising novel
therapeutic strategies to be used in the treatment of patients with non-small cell lung cancer …
therapeutic strategies to be used in the treatment of patients with non-small cell lung cancer …
Erlotinib in African Americans with advanced non–small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses
MA Phelps, TE Stinchcombe, JS Blachly… - Clinical …, 2014 - Wiley Online Library
Prospective studies on epidermal growth factor receptor (EGFR) inhibitors in African
Americans with non–small cell lung cancer (NSCLC) have not previously been performed. In …
Americans with non–small cell lung cancer (NSCLC) have not previously been performed. In …